Jun 19, 2018

Medtronic Introduces Updated iPro(TM)2 myLog App with FoodPrint(TM) Report Enhancing Diagnostic CGM for People with Diabetes

Expanded Relationship with Nutrino's FoodPrint Will Leverage Food Data Analytics Across Diabetes Portfolio

DUBLIN - June 19, 2018 - Medtronic (NYSE:MDT), the global leader in medical technology, today announced the availability of the updated iPro(TM)2 myLog app with FoodPrint(TM) Report. The iPro2...

DUBLIN - June 19, 2018 - Medtronic (NYSE:MDT), the global leader in medical technology, today announced the availability of the updated iPro(TM)2 myLog app with FoodPrint(TM) Report. The iPro2 myLog app offers a simple way for clinics to import patients' logged data during their professional iPro2 continuous glucose monitoring (CGM) evaluation. With the addition of the FoodPrint report, patients' meals are graded based on their body's unique glucose reaction, making it easy for them to understand the link between meals and glucose variability.

The iPro2 myLog app, now powered by Nutrino, a leading AI (artificial intelligence) personalized nutrition analysis platform, is used during a professional iPro2 CGM evaluation for the patient to log their blood glucose (BGs), food and activity. Meal logging is easy; patients simply take a photo of each meal and snack. Upon completion of the 6-day CGM evaluation, the information from the app is synchronized with sensor glucose data and creates two unique reports - the Pattern Snapshot report and the new FoodPrint report. The Pattern Snapshot report shows critical glucose information such as time in target glucose range, identified patterns of glucose variability, and a clear graph of the full glucose tracing. The FoodPrint report shows pictures of meals taken for breakfast, lunch and dinner and scores (A, B, C, D or F) each meal based on the body's glucose reaction. Together these reports help the physician and the patient work together to develop a personalized therapy and treatment plan.

"By making it easier to communicate relevant, personal insights about food's impact on diabetes, Medtronic arms physicians and diabetes educators with a powerful coaching tool that will help drive positive behavior change," said Sheri Dodd, vice president and general manager for Non-Intensive Diabetes Therapies (NDT). "Our partnership with Nutrino to infuse more detail about diet's impact on glucose furthers our goal to make glucose a vital sign in the treatment of diabetes."

Recognizing the important and intertwined impact that food has on diabetes, Medtronic has expanded its partnership with Nutrino, a leader in food data analytics with its flagship FoodPrint technology. Following two years of successful partnering and results, this expanded relationship will embed food data and FoodPrint insights across all the Diabetes Group businesses.

"We are proud to partner with Medtronic to deliver insights through the FoodPrint report, which can help people across the diabetes spectrum to better understand their responses to particular foods," said Yael Glassman, CEO of Nutrino Health. "We're confident that the addition of FoodPrint into the iPro2 professional CGM evaluation will have a positive impact for individuals living with type 2 diabetes."

About Nutrino
Nutrino is a leading provider of nutrition-related data services, analytics, and technologies. At its core, Nutrino strives for improved universal health by enabling AI-led analysis of how nutritional intake will affect a person's health. Nutrino has also built a leading food database and nutrition data insights platform, collating data from millions of access points and food items globally. Nutrino helps people discover their FoodPrint, a personalized assessment of their personal response to different foods. Smarter about food and smarter about people, Nutrino's revolutionary approach uncovers connections of the way individuals and groups metabolize and respond to foods. Nutrino is building a global FoodPrint. To find out more, click here.

About Diabetes Group at Medtronic
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.



Pamela Reese
Public Relations

Ryan Weispfenning
Investor Relations

Jill Burkes
Public Relations

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medtronic plc via Globenewswire